01 1Amphastar Nanjing Pharmaceuticals, Inc.
02 1Novo Nordisk A/S
01 1Degludec
02 1Insulin Degludec
01 1Denmark
02 1U.S.A
NDC Package Code : 52221-127
Start Marketing Date : 2022-10-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 0420-9007
Start Marketing Date : 2012-07-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
A insulin degludec manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of insulin degludec, including repackagers and relabelers. The FDA regulates insulin degludec manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. insulin degludec API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of insulin degludec manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A insulin degludec supplier is an individual or a company that provides insulin degludec active pharmaceutical ingredient (API) or insulin degludec finished formulations upon request. The insulin degludec suppliers may include insulin degludec API manufacturers, exporters, distributors and traders.
click here to find a list of insulin degludec suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing insulin degludec as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for insulin degludec API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture insulin degludec as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain insulin degludec and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a insulin degludec NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of insulin degludec suppliers with NDC on PharmaCompass.
We have 2 companies offering insulin degludec
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
